Modified phages: Novel antimicrobial agents to combat infectious diseases

Biotechnology Advances

Volumn 29, Issue 6, 2011, Pages 732-738

  Moradpour, Zahra ^a,b   Ghasemian, Abdollah ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bacterial resistance; Modified phages; Phage therapy

Indexed keywords

ANTI-MICROBIAL AGENT; ANTIBIOTIC-RESISTANT BACTERIA; BACTERIAL RESISTANCE; BACTERICIDAL AGENT; GENETICALLY MODIFIED; IN-VITRO; INFECTIOUS DISEASE; MODIFIED PHAGES; PHAGE THERAPY; SYNTHETIC BIOLOGY;

ANTIBIOTICS; BACTERICIDES; GENETIC ENGINEERING;

BACTERIOPHAGES;

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BIOTECHNOLOGY; GENETIC ENGINEERING; INFECTIOUS DISEASE; MOLECULAR ANALYSIS; RESEARCH WORK;

ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; COMMUNICABLE DISEASE; GENE THERAPY; REVIEW;

ANTI-INFECTIVE AGENTS; BACTERIOPHAGES; COMMUNICABLE DISEASES; DRUG RESISTANCE, BACTERIAL; GENE THERAPY;

BACTERIA (MICROORGANISMS);

EID: 80053440052     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.06.003     Document Type: Review

References (86)

1. Abedon S.T. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis 2009, 6:807-815.
2. Boratynski J., Syper D., Weber-Dabrowska B., Lusiak-Szelachowska M., Pozniak G., Gorski A. Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 2004, 9:253-259.
3. Bren L. Bacteria-eating virus approved as food additive. FDA Consum 2007, 41:20-22.
4. Budynek P., Dabrowska K., Skaradzinski G., Gorski A. Bacteriophages and cancer. Arch Microbiol 2010, 192:315-320.
5. Bull J.J., Vimr E.R., Molineux I.J. A tale of tails: sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli. Virology 2010, 398:79-86.
6. Cairns B.J., Payne R.J. Bacteriophage therapy and the mutant selection window. Antimicrob Agents Chemother 2008, 52:4344-4350.
7. Cao J., Sun Y., Berglindh T., Mellgard B., Li Z., Mardh B., et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochim Biophys Acta 2000, 1474:107-113.
8. Capparelli R., Ventimiglia I., Roperto S., Fenizia D., Iannelli D. Selection of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin Microbiol Infect 2006, 12:248-253.
9. Capparelli R., Nocerino N., Iannaccone M., Ercolini D., Parlato M., Chiara M., et al. Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy. J Infect Dis 2010, 201:52-61.
10. Capparelli R., Nocerino N., Lanzetta R., Silipo A., Amoresano A., Giangrande C., et al. Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice. PLoS One 2010, 5:e11720.
11. Carlton R.M. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz). 1999, 47:267-274.
12. Carlton RM. Antibacterial therapy with bacteriophage physico-chemically altered by pegylation to delay inactivation by the host defense system C12N 15/64; C12N 7/00 ed. United States 2008.
13. Carlton R.M., Noordman W.H., Biswas B., de Meester E.D., Loessner M.J. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol 2005, 43:301-312.
14. Carson C.F., Riley T.V. Non-antibiotic therapies for infectious diseases. Commun Dis Intell 2003, 27(Suppl):S143-S146.
15. Chen J., Novick R.P. Phage-mediated intergeneric transfer of toxin genes. Science 2009, 323:139-141.
16. Chibani-Chennoufi S., Sidoti J., Bruttin A., Kutter E., Sarker S., Brussow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 2004, 48:2558-2569.
17. Dabrowska K., Skaradzinski G., Kurzepa A., Owczarek B., Zaczek M., Weber-Dabrowska B., et al. The effects of staphylococcal bacteriophage lysates on cancer cells in vitro. Clin Exp Med 2010, 10:81-85.
18. Debattista J. Phage therapy: where East meets West. Expert Rev Anti Infect Ther 2004, 2:815-819.
19. Denou E., Bruttin A., Barretto C., Ngom-Bru C., Brussow H., Zuber S. T4 phages against Escherichia coli diarrhea: potential and problems. Virology 2009, 388:21-30.
20. Evans T.J., Trauner A., Komitopoulou E., Salmond G.P. Exploitation of a new flagellatropic phage of Erwinia for positive selection of bacterial mutants attenuated in plant virulence: towards phage therapy. J Appl Microbiol 2010, 108:676-685.
21. Falconer S.B., Brown E.D. New screens and targets in antibacterial drug discovery. Curr Opin Microbiol 2009, 12:497-504.
22. Fischetti V.A., Nelson D., Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat Biotechnol 2006, 24:1508-1511.
23. Gill J.J., Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 2009, 11:2-14.
24. Goodridge L.D. Designing phage therapeutics. Curr Pharm Biotechnol 2010, 11:15-27.
25. Gorski A., Miedzybrodzki R., Borysowski J., Weber-Dabrowska B., Lobocka M., Fortuna W., et al. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 2009, 10:766-774.
26. Hagens S., Blasi U. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 2003, 37:318-323.
27. Hagens S., Loessner M.J. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 2010, 11:58-68.
28. Hagens S., Habel A., Von Ahsen U., Von Gabain A., Blasi U. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004, 48:3817-3822.
29. Hagens S., Habel A., Blasi U. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microb Drug Resist 2006, 12:164-168.
30. Heilmann S., Sneppen K., Krishna S. Sustainability of virulence in a phage-bacterial ecosystem. J Virol 2010, 84:3016-3022.
31. Hill C. Bacteriophage and bacteriophage resistance in lactic acid bacteria. FEMS Microbiol Rev 1993, 12:87-108.
32. Hirabayashi M., Oiwa K., Nishikawa A., Tanaka F., Hagiya M. Toward self-assembly of phage-like nanorobot. Nanotechnology 2009, 530-535. Genoa.
33. Housby J.N., Mann N.H. Phage therapy. Drug Discov Today 2009, 14:536-540.
34. Hyman P., Abedon S.T. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 2010, 70:217-248.
35. Kamiji M.M., de Oliveira R.B. Non-antibiotic therapies for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2005, 17:973-981.
36. Kasparek P., Pantucek R., Kahankova J., Ruzickova V., Doskar J. Genome rearrangements in host-range mutants of the polyvalent staphylococcal bacteriophage 812. Folia Microbiol (Praha) 2007, 52:331-338.
37. Knezevic P., Kostanjsek R., Obreht D., Petrovic O. Isolation of Pseudomonas aeruginosa specific phages with broad activity spectra. Curr Microbiol 2009, 59:173-180.
38. Kropinski A.M. Phage therapy - everything old is new again. Can J Infect Dis Med Microbiol 2006, 17:297-306.
39. Krylov V.N. Phage therapy in terms of bacteriophage genetics: hopes, perspectives, safety, limitations. Genetika 2001, 37:869-887.
40. Kumari S., Harjai K., Chhibber S. Isolation and characterization of Klebsiella pneumoniae specific bacteriophages from sewage samples. Folia Microbiol (Praha) 2010, 55:221-227.
41. Kunisaki H., Tanji Y. Intercrossing of phage genomes in a phage cocktail and stable coexistence with Escherichia coli O157:H7 in anaerobic continuous culture. Appl Microbiol Biotechnol 2010, 85:1533-1540.
42. Kurzepa A., Dabrowska K., Switala-Jelen K., Gorski A. Molecular modification of T4 bacteriophage proteins and its potential application - review. Folia Microbiol (Praha) 2009, 54:5-15.
43. Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
44. Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010, 8:317-327.
45. Li Z., Tolba M., Griffiths M., van de Ven T.G. Effect of unassembled phage protein complexes on the attachment to cellulose of genetically modified bacteriophages containing cellulose binding modules. Colloids Surf B Biointerfaces 2010, 76:529-534.
46. Lu T.K., Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 2007, 104:11197-11202.
47. Lu T.K., Collins J.J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 2009, 106:4629-4634.
48. Lu TK, Collins JJ. Engineering synthetic bacteriophage to combat antibiotic-resistant bacteria. Bioengineering Conference, 2009 IEEE 35th Annual Northeast. 2009/05/26 ed. Boston, MA 2009b. p. 1-2.
49. Mahichi F., Synnott A.J., Yamamichi K., Osada T., Tanji Y. Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett 2009, 295:211-217.
50. Mårdh S (SE). Recombinant phages. United States 2002.
51. Marzari R., Sblattero D., Righi M., Bradbury A. Extending filamentous phage host range by the grafting of a heterologous receptor binding domain. Gene 1997, 185:27-33.
52. Matsuda T., Freeman T.A., Hilbert D.W., Duff M., Fuortes M., Stapleton P.P., et al. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 2005, 137:639-646.
53. Matsuzaki S., Rashel M., Uchiyama J., Sakurai S., Ujihara T., Kuroda M., et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 2005, 11:211-219.
54. Merabishvili M., Pirnay J.P., Verbeken G., Chanishvili N., Tediashvili M., Lashkhi N., et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009, 4:e4944.
55. Merril CRR (MD), Carlton, Richard M. (Port Washington, NY), Adhya, Sankar L. (Gaithersburg, MD). Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic. United States: Exponential Biotherapies, Inc. (New York, NY),The United States of America as represented by the Secretary of the (Washington, DC); 1998.
56. Merril CRR (MD, US), Carlton, Richard M. (Port Washington, NY, US), Adhya, Sankar L. (Gaithersburg, MD, US). Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system. United States 2005.
57. Merril C.R., Biswas B., Carlton R., Jensen N.C., Creed G.J., Zullo S., et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 1996, 93:3188-3192.
58. Merril C.R., Scholl D., Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003, 2:489-497.
59. Molenaar T.J., Michon I., de Haas S.A., van Berkel T.J., Kuiper J., Biessen E.A. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 2002, 293:182-191.
60. Moradpour Z., Sepehrizadeh Z., Rahbarizadeh F., Ghasemian A., Yazdi M.T., Shahverdi A.R. Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli. FEMS Microbiol Lett 2009, 296:67-71.
61. Niederman M.S. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001, 29:N114-N120.
62. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009, 78:119-146.
63. O'Flaherty S., Ross R.P., Meaney W., Fitzgerald G.F., Elbreki M.F., Coffey A. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol 2005, 71:1836-1842.
64. Parisien A., Allain B., Zhang J., Mandeville R., Lan C.Q. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 2008, 104:1-13.
65. Pepin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
66. Skurnik M., Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 2006, 296:5-14.
67. Skurnik M., Pajunen M., Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett 2007, 29:995-1003.
68. Smith H.W., Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128:307-318.
69. Smith H.W., Huggins M.B., Shaw K.M. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Microbiol 1987, 133:1127-1135.
70. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today 2005, 10:807-809.
71. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45:649-659.
72. Summers W.C. Bacteriophage therapy. Annu Rev Microbiol 2001, 55:437-451.
73. Tanji Y., Shimada T., Yoichi M., Miyanaga K., Hori K., Unno H. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol 2004, 64:270-274.
74. Then R.L., Sahl H.G. Anti-infective strategies of the future: is there room for species-specific antibacterial agents?. Curr Pharm Des 2010, 16:555-566.
75. Twest R., Kropinski A.M. Bacteriophage enrichment from water and soil 2008, 15-21.
76. Uchiyama J., Maeda Y., Takemura I., Chess-Williams R., Wakiguchi H., Matsuzaki S. Blood kinetics of four intraperitoneally administered therapeutic candidate bacteriophages in healthy and neutropenic mice. Microbiol Immunol 2009, 53:301-304.
77. Vieira J., Messing J. Production of single-stranded plasmid DNA. Methods Enzymol 1987, 153:3-11.
78. Vitiello C.L., Merril C.R., Adhya S. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res 2005, 114:101-103.
79. Weber W., Fussenegger M. The impact of synthetic biology on drug discovery. Drug Discov Today 2009, 14:956-963.
80. Weiss G.A., Sidhu S.S. Design and evolution of artificial M13 coat proteins. J Mol Biol 2000, 300:213-219.
81. Westwater C., Kasman L.M., Schofield D.A., Werner P.A., Dolan J.W., Schmidt M.G., et al. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 2003, 47:1301-1307.
82. Withington R. Regulatory issues for phage-based clinical products. J Chem Technol Biotechnol 2001, 76:673-676.
83. Yacoby I., Benhar I. Targeted filamentous bacteriophages as therapeutic agents. Expert Opin Drug Deliv 2008, 5:321-329.
84. Yacoby I., Shamis M., Bar H., Shabat D., Benhar I. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob Agents Chemother 2006, 50:2087-2097.
85. Young R., Blasi U. Holins: form and function in bacteriophage lysis. FEMS Microbiol Rev 1995, 17:191-205.
86. Young I., Wang I., Roof W.D. Phages will out: strategies of host cell lysis. Trends Microbiol 2000, 8:120-128.